Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICA^TM), will be presented virtually in a “New Drugs on the Horizon” session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and Bicycle Toxin Conjugates (BTCs), will also be covered in a late-breaking mini-symposium, as well as in five e-posters.

“Our TICA platform has made significant progress, and we are thrilled to present information about the discovery of BT7480, as well as preclinical data across multiple programs in our immuno-oncology pipeline,” said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics. “These presentations highlight the potential utility of Bicycle-based therapeutic candidates for treating multiple tumor types via diverse mechanisms as we pursue our goal of improving the treatment paradigm for patients with cancer.”

Bicycle TICAs are potent, fully synthetic compounds that represent an immuno-oncology approach engineered to overcome the limitations of other immunomodulatory mechanisms. Bicycles are small, structurally constrained peptides discovered via phage display and optimized using structure-driven design and medicinal chemistry approaches. Bicycle has applied this disruptive technology by identifying CD137 Bicycles and chemically linking these to tumor antigen binding Bicycles to generate multifunctional molecules that induce tumor antigen-dependent, tumor-localized agonism of CD137. Bicycle expects BT7480 to enter the clinic in the second half of 2021.

Details on Bicycle’s presentations and posters at AACR are as follows:

Poster Title: Molecular-based enrichment strategy for Nectin-4 targeted Bicycle toxin conjugate BT8009
Abstract #: 391
Session, Date and Time: Biomarkers Predictive of Therapeutic Benefit, April 10, 8:30 AM

Poster Title: Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist (TICA)
Poster #: 1728
Session, Date and Time: Immunomodulatory Agents and Interventions, April 10, 8:30 AM

Poster Title: Microinjection of Nectin-4/CD137 tumor-targeted immune cell agonist (TICA) activates the local tumor microenvironment